EGFR-TKIs resistance via EGFR-independent signaling pathways
- PMID: 29455669
- PMCID: PMC5817859
- DOI: 10.1186/s12943-018-0793-1
EGFR-TKIs resistance via EGFR-independent signaling pathways
Abstract
Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer. Unfortunately, the majority of these patients ultimately develop to the acquired resistance after a period of treatment. Two central mechanisms are involved in the resistant process: EGFR secondary mutations and bypass signaling activations. In an EGFR-dependent manner, acquired mutations, such as T790 M, interferes the interaction between TKIs and the kinase domain of EGFR. While in an EGFR-independent manner, dysregulation of other receptor tyrosine kinases (RTKs) or abnormal activation of downstream compounds both have compensatory functions against the inhibition of EGFR through triggering phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) signaling axes. Nowadays, many clinical trials aiming to overcome and prevent TKIs resistance in various cancers are ongoing or completed. EGFR-TKIs in accompany with the targeted agents for resistance-related factors afford a promising first-line strategy to further clinical application.
Keywords: Bypass signalings; Downstream compounds; Drug resistance; EGFR; ErbB; RTKs; TKIs.
Conflict of interest statement
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5817859/bin/12943_2018_793_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5817859/bin/12943_2018_793_Fig2_HTML.gif)
Similar articles
-
Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.Clin Cancer Res. 2014 Dec 1;20(23):5898-907. doi: 10.1158/1078-0432.CCR-13-2437. Epub 2014 Oct 10. Clin Cancer Res. 2014. PMID: 25303979 Free PMC article. Review.
-
Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16. Clin Lung Cancer. 2013. PMID: 23332287 Review.
-
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.Curr Opin Oncol. 2015 Mar;27(2):94-101. doi: 10.1097/CCO.0000000000000164. Curr Opin Oncol. 2015. PMID: 25611025 Review.
-
Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.Sci Signal. 2013 Sep 24;6(294):re6. doi: 10.1126/scisignal.2004652. Sci Signal. 2013. PMID: 24065147 Free PMC article. Review.
-
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.Clin Cancer Res. 2018 Aug 15;24(16):4044-4055. doi: 10.1158/1078-0432.CCR-17-3674. Epub 2018 May 14. Clin Cancer Res. 2018. PMID: 29760222
Cited by
-
Immunohistochemical Expression Levels of Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Ki-67 in Canine Cutaneous Squamous Cell Carcinomas.Curr Issues Mol Biol. 2024 May 19;46(5):4951-4967. doi: 10.3390/cimb46050297. Curr Issues Mol Biol. 2024. PMID: 38785565 Free PMC article.
-
Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells.World J Oncol. 2024 Jun;15(3):492-505. doi: 10.14740/wjon1873. Epub 2024 May 7. World J Oncol. 2024. PMID: 38751701 Free PMC article.
-
Interstitial Fluid Shear Stress Induces the Synthetic Phenotype Switching of VSMCs to Release Pro-calcified Extracellular Vesicles via EGFR-MAPK-KLF5 Pathway.Int J Biol Sci. 2024 Apr 29;20(7):2727-2747. doi: 10.7150/ijbs.90725. eCollection 2024. Int J Biol Sci. 2024. PMID: 38725857 Free PMC article.
-
Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.Exp Mol Med. 2024 May;56(5):1137-1149. doi: 10.1038/s12276-024-01221-2. Epub 2024 May 1. Exp Mol Med. 2024. PMID: 38689087 Free PMC article.
-
A radiobiological perspective on radioresistance or/and radiosensitivity of head and neck squamous cell carcinoma.Rep Pract Oncol Radiother. 2024 Feb 16;28(6):809-822. doi: 10.5603/rpor.99355. eCollection 2023. Rep Pract Oncol Radiother. 2024. PMID: 38515813 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous